Company Neurizon Therapeutics Limited

NUZ

AU0000357261

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 10:08:12 14/01/2026 am IST			5-day change	1st Jan Change
0.0820 ^AUD	0.00%		+2.50%	-3.53%

02/01	FDA Denies Neurizon Therapeutics' Request for Fast Track Designation for ALS Treatment Candidate	MT
02/01	Neurizon Therapeutics says US FDA denies Fast Track designation for NUZ-001	RE

Business description: Neurizon Therapeutics Limited

Neurizon Therapeutics Ltd, formerly PharmAust Limited, is an Australia-based clinical-stage biotechnology company. The Company is engaged in advancing treatments for neurodegenerative diseases. The Company is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.

Number of employees: 4

Sales by Activity: Neurizon Therapeutics Limited

Fiscal Period: June	2021 (AUD)	2022 (AUD)	2023 (AUD)	2024 (AUD)	2025 (AUD)
Corporate & Research	6L	8L	10L	8L	15.38L
Pharmaceutical - Epichem	31.36L	37.58L	31.13L	-	-
Inter-Segment Elimination	-71.31T	-82.03T	-2L	-	-

See all business segments

Geographical breakdown of sales: Neurizon Therapeutics Limited

Fiscal Period: June	2021 (AUD)	2022 (AUD)	2023 (AUD)	2024 (AUD)	2025 (AUD)
Sweden	-	3L	-	-	-
USA	1L	2L	1L	-	-
Australia	7L	17.37L	26.87L	-	-
Switzerland	11.3L	10.43L	17.28T	-	-
Others	2L	96.09T	18.76T	-	-

See all geographic segments

Executive Committee: Neurizon Therapeutics Limited

Manager	Title	Age	Since
Michael Thurn CEO	Chief Executive Officer	-	01/09/2023
Daniel O'Connell DFI	Director of Finance/CFO	-	22/04/2025
Stefan Ross SEC	Corporate Secretary	-	24/05/2024

See NEURIZON THERAPEUTICS LIMITED governance

Composition of the Board of Directors: Neurizon Therapeutics Limited

Director	Title	Age	Since
Michael Thurn BRD	Director/Board Member	-	31/05/2024
Kathryn MacFarlane BRD	Director/Board Member	60	17/06/2024
Marcus Hughes BRD	Director/Board Member	-	09/05/2024
Sergio Duchini CHM	Chairman	-	17/05/2024

Composition of the Board of Directors

Shareholders: Neurizon Therapeutics Limited

Name	Equities	%	Valuation
Loon Tan Chek 5.199 %	3,90,00,000	5.199 %	2 M $
Roger Aston 2.04 %	1,53,01,991	2.04 %	867 317 $
Marcus Hughes 1.96 %	1,47,00,943	1.96 %	833 249 $
Sam Wright 0.678 %	50,85,470	0.678 %	288 244 $
Michael Thurn 0.3825 %	28,69,276	0.3825 %	162 631 $

List of NEURIZON THERAPEUTICS LIMITED shareholders

Company details: Neurizon Therapeutics Limited

Neurizon Therapeutics Ltd.

385 Bourke Street

3000, Melbourne

+61 3 9692 7222

http://www.pharmaust.com

address Neurizon Therapeutics Limited(NUZ)

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
NEURIZON THERAPEUTICS LIMITED	0.00%	+2.50%	-48.75%	-1.20%	3.37Cr
ELI LILLY AND COMPANY	-0.85%	-2.38%	+45.21%	+202.37%	96TCr
JOHNSON & JOHNSON	+0.83%	+3.64%	+48.57%	+24.77%	51TCr
ABBVIE INC.	+0.30%	-5.06%	+26.24%	+45.01%	39TCr
ROCHE HOLDING AG	+1.23%	+1.92%	+30.87%	+17.01%	36TCr
ASTRAZENECA PLC	+1.48%	+0.39%	+34.34%	+22.30%	29TCr
NOVARTIS AG	+1.80%	+1.90%	+28.47%	+34.26%	27TCr
MERCK & CO., INC.	+0.02%	+0.26%	+9.26%	-1.42%	27TCr
NOVO NORDISK A/S	-0.98%	+3.12%	-36.21%	-20.68%	27TCr
AMGEN INC.	+0.22%	-5.04%	+21.47%	+20.42%	17TCr
Average	+0.50%	+1.52%	+15.95%	+34.28%	35.05TCr
Weighted average by Cap.	+0.34%	+1.61%	+29.80%	+69.95%